Chemomab Therapeutics (CMMB) EPS (Basic) Growth (1y) (2018 - 2025)
Chemomab Therapeutics (CMMB) EPS (Basic) Growth (1y) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | -16.29% |
| 10 | Chemomab Therapeutics | 13.08 Mn | 2.71 Mn | - | -55.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 366.99% |
| Sep 30, 2025 | -64.52% |
| Dec 31, 2024 | 7,223,623.74% |
| Sep 30, 2024 | 110.16% |
| Mar 31, 2024 | -65.47% |
| Dec 31, 2023 | -59.90% |
| Sep 30, 2023 | -46.47% |
| Mar 31, 2023 | 276.15% |
| Dec 31, 2022 | 249.37% |
| Sep 30, 2022 | 371.26% |
| Mar 31, 2022 | -105.85% |
| Dec 31, 2021 | 99.94% |
| Sep 30, 2021 | 21.10% |
| Jun 30, 2021 | -75.83% |
| Mar 31, 2021 | 4.83% |
| Dec 31, 2020 | -9,047.05% |
| Sep 30, 2020 | -569,634.88% |
| Jun 30, 2020 | -2,162,100.00% |
| Mar 31, 2020 | -106.62% |
| Dec 31, 2019 | -33,954,217.33% |